RxDoctor Payments Data

Germaine Thurmond

Family · Slidell, LANPI 1235614066

Payments from drug & device makers

$8,308in general payments, 2019–2025

Across 455 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$838
  • Lilly USA, LLC$752
  • AbbVie$678
  • Bayer$550
  • Novo Nordisk$549
  • Merck$378
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$8,308100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)22$838
Lilly USA, LLC38$752
AbbVie45$678
Bayer30$550
Novo Nordisk39$549
Merck21$378
Johnson & Johnson(2 entities)21$368
Ironwood Pharmaceuticals, Inc16$311
Amgen18$293
Novartis15$255
GSK15$235
Otsuka America Pharmaceutical, Inc.13$220
Pfizer12$216
E.r. Squibb & Sons, L.L.C.10$177
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC10$173
Exact Sciences8$157
Daiichi Sankyo Inc.7$131
Abbott6$128
Sanofi8$122
Bristol Myers Squibb6$108
Boehringer Ingelheim5$97
Pharmacyclics LLC, An Abbvie Company5$91
Astellas Pharma US Inc5$81
Kyowa Kirin, Inc.4$71
Sanofi-aventis U.S. LLC4$70
Seagen Inc.4$68
Incyte Corporation4$64
Karyopharm Therapeutics Inc.4$60
Takeda Pharmaceuticals U.S.A., Inc.3$60
Dexcom, Inc.2$56
Beigene USA, Inc.3$55
Genentech USA, Inc.3$53
Morphosys, US Inc.3$51
Coherus Oncology, Inc.3$51
Puma Biotechnology, Inc.2$44
Dova Pharmaceuticals3$43
Edwards Lifesciences1$40
Blueprint Medicines Corporation3$39
Eisai Inc.2$37
Biohaven Pharmaceutical Holding Company Ltd.2$37
Amarin Pharma, Inc.2$37
Exelixis Inc.2$34
Deciphera Pharmaceuticals Inc.2$32
Rigel Pharmaceuticals, Inc.2$30
Sunovion Pharmaceuticals Inc.2$29
Axsome Therapeutics, Inc.1$25
Supernus Pharmaceuticals, Inc.1$24
Phathom Pharmaceuticals, Inc.3$24
TG Therapeutics, Inc.1$23
Ardelyx, Inc.1$20
Epizyme, Inc.1$20
Tactile Systems Technology Inc1$20
Myovant Sciences Inc.1$19
ADC Therapeutics America, Inc.1$19
Esperion Therapeutics, Inc.1$18
Kowa Pharmaceuticals America, Inc.1$18
Gilead1$18
Regeneron Healthcare Solutions, Inc.1$18
Sirtex Medical Inc1$17
G1 Therapeutics, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,308 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$10,258
Medicare patients
91
Services billed
160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide41$59,170
OzempicSemaglutide20$30,514
MounjaroTirzepatide19$21,972
JardianceEmpagliflozin18$12,902
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$11,925
FarxigaDapagliflozin Propanediol11$7,112
LinzessLinaclotide12$6,082
BelsomraSuvorexant11$4,693
Albuterol Sulfate HfaAlbuterol Sulfate65$2,667
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,190
Gabapentin96$705
Trazodone Hcl53$688
Losartan Potassium91$661
Atorvastatin Calcium104$632
Rosuvastatin Calcium40$629

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$752$81,14260 claims
Novo NordiskOzempic$549$30,51420 claims
Boehringer IngelheimJardiance$97$12,90218 claims
GSKTrelegy Ellipta$235$11,92515 claims
AstraZenecaFarxiga$838$7,11211 claims
AbbVieLinzess$678$6,08212 claims
MerckBelsomra$378$4,69311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.

Other family in Slidell

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →